In rodent models of T2DM, TRPV4 agonists promote vasodilation and improve cardiovascular function, whereas TRPV4 antagonists reduce HFD-induced obesity, insulin resistance, DN, retinopathy and neuropathy (Ref. This evidence concerns the gene TRPV4 and obesity due to melanocortin 4 receptor deficiency.